Shots:

• GSK to provide pandemic adjuvant system to Clover to evaluate S-Trimer in preclinical studies while Clover has largest commercial-scale cGMP biomanufacturing capabilities in China involved in rapid scale-up and produce new coronavirus vaccine
• The focus of the collaboration is to evaluate the combination of GSK’s pandemic adjuvant system with Clover’s S-Trimer as a vaccine candidate utilizing its own Timer-Tag technology to develop vaccines for corona virus
• Trimer-Tag technology is a drug development platform involved in production of novel covalently-trimerized fusion proteins targeted to these previously undruggable pathways

Click here to read full press release/ article

Ref: GSK | Image: GSK